ArticleCancer management and research2025
Multicenter Development of a Clinical-Molecular Nomogram for Predicting Survival in Lung Cancer Brain Metastasis Patients.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer brain metastasis (LCBM) accounts for 40-50% of intracranial malignancies, with emerging evidence of alternative metastatic pathways circumventing the blood-brain barrier. Existing prognostic models lack validation in Asian populations and molecular stratification. This multicenter study aimed to develop a clinical nomogram integrating clinicopathological and molecular determinants for personalized LCBM management. Methods: Retrospective analysis of 522 surgically treated LCBM patients (2015-2021) from four Chinese institutions was conducted. Patients were randomized 7:3 into training (n=365) and validation (n=157) cohorts. Multivariate Cox regression identified independent prognostic factors, which were incorporated into a nomogram predicting 6-/12-/18-month overall survival (OS). Model performance was assessed via time-dependent ROC curves (AUC), calibration plots, and decision curve analysis (DCA). Results: The median OS after neurosurgery was 9 months (range: 4-18 months), with 6-, 12-, and 18-month survival rates of 86.2%, 46.7%, and 17.2%, respectively. Independent predictive factors included brain metastasis size ≥5 cm, Leptomeningeal metastasis(LM), EGFR mutation with TKI treatment, and extracranial metastases. The nomogram demonstrated robust discriminative ability and calibration. EGFR-mutant patients receiving postoperative TKIs showed significantly prolonged survival attributable to enhanced blood-brain barrier permeability. Finally, the authors developed a web-based dynamic nomogram for LCBM patients to facilitate clinical implementation. Conclusion: This study establishes a validated prognostic model integrating tumor burden, EGFR mutation status, and metastatic patterns. It demonstrates that EGFR-guided TKI therapy and bone metastasis surveillance critically influence LCBM outcomes. The nomogram provides a quantifiable framework for risk-adapted therapeutic decisions, advancing precision oncology in neuro-oncology practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.